Phase I Study of Interleukin-12 in Combination With Rituximab in Patients With B-Cell Non-Hodgkin’s Lymphoma

Publication
Article
OncologyONCOLOGY Vol 15 No 3
Volume 15
Issue 3

Rituximab (Rituxan) is a genetically engineered chimeric murine/human monoclonal antibody that binds specifically to CD20 on pre-B and mature B lymphocytes. While binding of the Fab domain may induce apoptosis, the Fc domain recruits immune

Rituximab (Rituxan) is a genetically engineered chimericmurine/human monoclonal antibody that binds specifically to CD20 on pre-B andmature B lymphocytes. While binding of the Fab domain may induce apoptosis, theFc domain recruits immune effector functions to mediate lysis of the B cell.Interleukin-12 (IL-12) has been shown to facilitate cytolytic T-cell responses,promote the development of Th1-type helper T cells, enhance the lytic activityof natural killer (NK) cells, and induce the secretion of interferon gamma byboth T and NK cells. Therefore, we hypothesized that combining IL-12 withrituximab would augment the immune mediated cell lysis induced by rituximab.

We conducted a phase I study of IL-12 in combination withrituximab in adult patients with B-cell non-Hodgkin’s lymphoma to determinethe optimal immunologic dose of this combination. Rituximab was administered ata fixed dose of 375 mg/m2 by intravenous infusion weekly for 4 weeks, whileIL-12 was given subcutaneously twice weekly for up to 6 months. The startingdose of IL-12 was 30 ng/kg; this was escalated with each cohort of six patientsto a maximum of 500 ng/kg.

Forty-three patients (4 small lymphocytic, 20 follicular, 10diffuse large cell, 6 mantle cell, 2 lymphoplasmacytic, 1 T-cell-rich B cell)were treated. Constitutional symptoms and liver enzyme elevations were found tobe dose-limiting. A greater than 100% increase from baseline in the serum levelsof interferon gamma and inducible protein 10 (IP-10) in response to IL-12 wereseen at IL-12 doses of 100, 300, and 500 ng/kg. Significant constitutionalsymptoms and liver enzyme elevations were seen at the 300-ng/kg dose level,necessitating a dose reduction in 4 of 9 patients.

Dose-limiting toxicity was seen at 500 ng/kg. As the goal of thestudy was to determine the optimal immunologic dose of IL-12 when given incombination with rituximab rather than the maximum tolerated dose, therecommended immunologic dose of IL-12 is therefore 100 ng/kg subcutaneouslytwice weekly.

Objective responses were seen in 29 of 43 patients (69%; 3/4small lymphocytic,  13/20 follicular, 6/10 large cell, 5/6 mantle cell, 1/2 lymphoplasmacytic, 1/1T-cell-rich B cell).

CONCLUSION: These data suggest that this is an activecombination. Further studies of this combination in B-cell non-Hodgkin’slymphoma are planned.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers